Pfizer Inc. (NYSE:PFE) trades at a considerable discount to AbbVie Inc. (NYSE:ABBV), despite both companies reporting growth ...

Pfizer (NYSE:PFE) agreed a research collaboration and licensing deal with Enodia Therapeutics to pursue Sec61-targeting small ...

Pfizer has a compelling risk-reward profile despite near-term COVID normalization and patent expiry headwinds. Find out why PFE stock is a Buy.

Pfizer is rated a Buy with new and acquired products generated $3.2B in Q2, growing 18% YoY and $13B annualized run-rate.

Pfizer's NYSE Composite context covers pharmaceutical operations, Tukysa approval, oncology research, vaccine development, patent exclusivity and dividend commitments across global healthcare markets.

Enodia Therapeutics will handle initial discovery work to identify, refine, and advance small-molecule candidates directed at ...

Pfizer Inc. (NYSE: PFE) will present data from more than 50 company-sponsored, investigator-sponsored and collaborative research abstracts across its infectious disease pipeline and portfolio at the ...

Pfizer Inc. (NYSE:PFE) has barely rewarded shareholders over the past year. That underperformance has left Pfizer looking ...

Under the terms of the pharma deal, Enodia will screen, optimize, and develop Sec61 inhibitor candidates against multiple ...

The HER2CLIMB-05 trial is a randomized, double blind, placebo-controlled, pivotal Phase 3 study evaluating the efficacy and safety of TUKYSA compared to placebo, both in combination with trastuzumab ...

Profit taking is hitting one of biotech’s hottest trades, and the selling is landing heaviest on the stock that ran the ...

The State of Florida filed a civil lawsuit Thursday against pharmaceutical manufacturer Pfizer Inc. and its chairman and chief executive officer, Albert Bourla, accusing the company of misleading the ...